BioNTech (NASDAQ:BNTX) Upgraded at Wall Street Zen

BioNTech (NASDAQ:BNTX - Get Free Report) was upgraded by equities research analysts at Wall Street Zen from a "sell" rating to a "hold" rating in a report released on Saturday.

Several other equities analysts have also commented on the stock. Leerink Partners set a $112.00 price target on shares of BioNTech in a research report on Monday. HC Wainwright upped their price target on BioNTech from $134.00 to $145.00 and gave the stock a "buy" rating in a research note on Thursday. BMO Capital Markets lifted their price objective on BioNTech from $130.00 to $143.00 and gave the company an "outperform" rating in a research note on Tuesday, March 11th. JPMorgan Chase & Co. reduced their price target on BioNTech from $120.00 to $116.00 and set a "neutral" rating on the stock in a research report on Thursday, May 22nd. Finally, Canaccord Genuity Group reaffirmed a "buy" rating and issued a $171.44 price objective on shares of BioNTech in a research report on Tuesday, March 11th. Five investment analysts have rated the stock with a hold rating, thirteen have issued a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $138.25.

BioNTech Stock Down 1.5%

Shares of NASDAQ BNTX opened at $108.49 on Friday. The firm has a market cap of $26.08 billion, a P/E ratio of -51.66 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a quick ratio of 7.21 and a current ratio of 7.33. BioNTech has a 1 year low of $76.53 and a 1 year high of $131.49. The firm's 50 day moving average price is $99.26 and its 200 day moving average price is $108.35.

BioNTech (NASDAQ:BNTX - Get Free Report) last announced its quarterly earnings data on Monday, March 10th. The company reported $1.08 EPS for the quarter, beating analysts' consensus estimates of $0.38 by $0.70. BioNTech had a negative return on equity of 2.35% and a negative net margin of 15.16%. The business had revenue of $1.19 billion during the quarter, compared to the consensus estimate of $1.24 billion. During the same quarter in the previous year, the business earned $1.90 earnings per share. The business's revenue for the quarter was down 19.5% on a year-over-year basis. As a group, sell-side analysts anticipate that BioNTech will post -3.88 earnings per share for the current year.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently modified their holdings of the business. FMR LLC grew its position in BioNTech by 22.2% in the 4th quarter. FMR LLC now owns 7,701,476 shares of the company's stock valued at $877,583,000 after buying an additional 1,401,547 shares in the last quarter. Flossbach Von Storch SE lifted its position in BioNTech by 1.1% in the fourth quarter. Flossbach Von Storch SE now owns 4,406,843 shares of the company's stock worth $502,160,000 after purchasing an additional 47,236 shares during the period. Capital International Investors boosted its stake in BioNTech by 38.6% during the 4th quarter. Capital International Investors now owns 1,415,566 shares of the company's stock valued at $161,304,000 after purchasing an additional 394,434 shares in the last quarter. BNP Paribas Financial Markets raised its stake in shares of BioNTech by 94.6% in the 1st quarter. BNP Paribas Financial Markets now owns 1,195,470 shares of the company's stock worth $108,859,000 after buying an additional 581,173 shares in the last quarter. Finally, Bank of New York Mellon Corp raised its stake in shares of BioNTech by 18,892.9% in the 1st quarter. Bank of New York Mellon Corp now owns 698,368 shares of the company's stock worth $63,593,000 after buying an additional 694,691 shares in the last quarter. Institutional investors own 15.52% of the company's stock.

BioNTech Company Profile

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.